18F-FDG与68Ga-PSMA PET/CT在乳头状肾细胞癌复发再分期中优于单独CT
本文报道一例77岁男性乳头状肾细胞癌患者,CT漏诊肺转移,经[18F]FDG PET/CT再分期发现,后接受舒尼替尼靶向治疗;随访中[68Ga]PSMA PET/CT在已知病灶外另发现CT漏诊的骨髓转移,提示两种分子影像在RCC再分期和疗效评估中优于传统影像。
要点
- 18F-FDG PET/CT可发现CT漏诊的乳头状RCC肺转移。
- 68Ga-PSMA PET/CT随访可发现CT漏诊的骨髓转移。
- 分子影像有助于RCC再分期及靶向治疗反应评估。
核心结论
- 18F-FDG与68Ga-PSMA PET/CT分子影像在RCC再分期和疗效评估中优于传统影像。
研究设计与样本
- 单个病例报告,描述一例77岁男性乳头状RCC患者的再分期与随访影像。
主要发现
- CT扫描漏诊了该患者的乳头状RCC肺转移,而18F-FDG PET/CT再分期成功发现。
- 患者接受舒尼替尼靶向治疗。
- 随访中68Ga-PSMA PET/CT在已知病灶之外发现了CT漏诊的骨髓转移。
临床怎么用
- 对乳头状RCC复发再分期,可考虑18F-FDG或68Ga-PSMA PET/CT以发现CT漏诊病灶。
- 随访中可用68Ga-PSMA PET/CT辅助评估靶向治疗反应及发现额外转移。
局限性
- 证据仅来自单个病例报告,结论外推需谨慎。
- 缺乏与CT的系统性对比数据及定量指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Renal cell carcinoma (RCC) shows variable FDG uptake; recently, PET/CT with prostate-specific membrane antigen (PSMA)-target radiotracers was demonstrated to be a promising tool in staging and restaging of RCC patients. We describe the case of a 77-year-old man with a lung metastasis of papillary RCC missed by CT scan who successfully underwent [18F]FDG PET/CT restaging. Targeted therapy with sunitinib was administered. A [68Ga]PSMA PET/CT performed during follow-up demonstrated, among the already known lesions, also a bone marrow metastasis, missed by previous CT scans. This case demonstrates that PET/CT molecular imaging with [18F]FDG and [68Ga]PSMA is superior to conventional imaging in RCC restaging and in assessing therapy response.
引用
- Gasparro D, Scarlattei M, Manuguerra R, et al. 18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence. Clin Nucl Med. 2021. PMID: 34374683. doi:10.1097/RLU.0000000000003660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。